Synthesis and antifungal activity of 1-[(2-benzyloxy)phenyl]-2-(azol-1-yl)ethanone derivatives: Exploring the scaffold flexibility

Chemical Biology and Drug Design

Volumn 78, Issue 6, 2011, Pages 979-987

  Emami, Saeed ^a   Kazemi Najafabadi, Motahare ^a   Pashangzadeh, Soughra ^a   Foroumadi, Alireza ^b   Faramarzi, Mohammad Ali ^b   Samadi, Nasrin ^c   Falahati, Mehraban ^b   Fateh, Roohollah ^b   Ashrafi Khozani, Mahtab ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1,2,4 triazole; 1H imidazole; Antifungal activity; Azole antifungals; Conformational study

Indexed keywords

1 [(2 BENZYLOXY)PHENYL] 2 (AZOL 1 YL)ETHANONE DERIVATIVE; 1 [2 (2 FLUOROBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (2 FLUOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (2,4 DICHLOROBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (2,4 DICHLOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (3 CHLOROBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (3 CHLOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (3 FLUOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (3 METHOXYBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (3,4 DICHLOROBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (3,4 DICHLOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (4 BROMOBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (4 CHLOROBENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1 [2 (4 CHLOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (4 FLUOROBENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 1 [2 (BENZYLOXY)PHENYL] 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE NITRATE; 1 [2 (BENZYLOXY)PHENYL] 2 (1H IMIDAZOL 1 YL)ETHANONE; 3' CHLORO 3 IMIDAZOLYLFLAVANONE; ANTIFUNGAL AGENT; FLUCONAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETOPHENONES; ANTIFUNGAL AGENTS; AZOLES; FUNGI; IMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

FUNGI;

EID: 81355147139     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01243.x     Document Type: Article

References (17)

1. Marr K.A. (2008) Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol;46:293-302.
2. Neely M.N., Ghannoum M.A. (2000) The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis;19:897-914.
3. Maertens J.A. (2004) History of the development of azole derivatives. Clin Microbiol Infect;10(Suppl. 1):1-10.
4. Bolouri F., Moghadami Tabrizi N., Davari Tanha F., Niroomand N., Azmoodeh A., Emami S., Falahati M., Sharifynia S., Safavi M., Shasiee A., Foroumadi A. (2009) Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iran J Pharm Res;8:307-313.
5. Emami S., Behdad M., Foroumadi A., Falahati M., Lotfali E., Sharifynia S. (2009) Design of conformationally constrained azole antifungals: Efficient synthesis and antifungal activity of trans-3-imidazolylflavanones. Chem Biol Drug Des;73:388-395.
6. Ogata M., Matsumoto H., Shimizu S., Kida S., Shiro M., Tawara K. (1987) Synthesis and antifungal activity of new 1-vinylimidazoles. J Med Chem;30:1348-1354.
7. Sobel J.D., Vazquez J.A. (2006) Contemporary Diagnosis and Management of Fungal Infections, 2nd edn. Newtown, PA: Handbooks in Health Care Company Publishers.
8. Emami S., Foroumadi A., Falahati M., Lotfali E., Rajabalian S., Ebrahimi S.-A., Farahyar S., Shafiee A. (2008) 2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents. Bioorg Med Chem Lett;18:141-146.
9. National Committee for Clinical Laboratory Standards (2006) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A2, Wayne, Pennsylvania, USA.
10. Espinel-Ingroff A., Fothergill A., Peter J., Rinaldi M.G., Walsh T.J. (2002) Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol;40:3204-3208.
11. Bryan J.D., Goldberg A.A., Wragg A.H. (1960) Synthesis of the 7-chloro-derivatives of chromone, flavone, and isoflavone. J Chem Soc;1279-1281.
12. King L.C., Ostrum G.K. (1964) Selective bromination with copper (II) bromide. J Org Chem;29:3459-3461.
13. Emami S., Shafiee A. (2001) Stereoselective syntheses of (E)- and (Z)-2, 3-dihydro-3-(1, 2, 4-triazolyl)-4H-1-benzopyran-4-one oxime ethers. Heterocycles;55:2059-2074.
14. Rossello A., Bertini S., Lapucci A., Macchia M., Martinelli A., Rapposelli S., Herreros E., Macchia B. (2002) Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem;45:4903-4912.
15. Proudfoot J.R. (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett;12:1647-1650.
16. Keller T.H., Pichota A., Yin Z. (2006) A practical view of 'druggability'. Curr Opin Chem Biol;10:357-361.
17. Lipinski C.A. (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol;1:337-341.